Dtsch Med Wochenschr 2012; 137(49): 2540-2542
DOI: 10.1055/s-0032-1327285
Endokrinologie und Diabetologie | Commentary
Endokrinologie
© Georg Thieme Verlag KG Stuttgart · New York

Neue Entwicklungen bei Hypophysenerkrankungen

New developments in pituitary diseases
M. Gruber
1   Medizinische Klinik und Poli- klinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
,
H. S. Willenberg
1   Medizinische Klinik und Poli- klinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
2   Klinik für Endokrinologie und Diabetologie, Heinrich-Heine-Universität Düsseldorf
,
S. R. Bornstein
1   Medizinische Klinik und Poli- klinik III, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2012 (online)

    Permissions and Reprints

Schlüsselwörter

Hypophysenadenom - Hypophyseninsuffizienz - Inzidentalome - Morbus Cushing - Akromegalie

Keywords

pituitary adenoma - hypopituitarism - incidentaloma - Cushing's syndrome - acromegaly
 

  • Literatur

  • 1 Bleicken B, Hahner S, Loeffler M et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010; 72: 297-304
    CrossrefGoogle Scholar
  • 2 Colao A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924
    CrossrefPubMedGoogle Scholar
  • 3 Elenkova A, Shabani R, Kalinov K et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 2012; 167: 17-25
    CrossrefGoogle Scholar
  • 4 Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96: 1633-1641
    CrossrefPubMedGoogle Scholar
  • 5 Fenske W, Quinkler M, Lorenz D et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome – revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011; 96: 1506-1515
    CrossrefGoogle Scholar
  • 6 Fernandez-Balsells MM, Murad MH, Barwise A et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas. J Clin Endocrinol Metab 2011; 96: 905-912
    CrossrefPubMedGoogle Scholar
  • 7 Fleseriu M, Biller BM, Findling JW et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049
    CrossrefPubMedGoogle Scholar
  • 8 Freda PU, Beckers AM, Katznelson L et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 894-904
    CrossrefPubMedGoogle Scholar
  • 9 Hahner S, Loeffler M, Bleicken B et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 2010; 162: 597-602
    CrossrefGoogle Scholar
  • 10 Halperin I, Aller J, Varela C et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf) 2012; 77: 275-280
    CrossrefGoogle Scholar
  • 11 Liu X, Kano H, Kondziolka D et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary 2012; Feb 3. [Epub ahead of print]
    Google Scholar
  • 12 Melmed S, Casanueva FF, Hoffman AR et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
    CrossrefGoogle Scholar
  • 13 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
    CrossrefGoogle Scholar
  • 14 Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49
    CrossrefGoogle Scholar
  • 15 Ortiz LD, Syro LV, Scheithauer BW et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 2012; 67 (Suppl. 01) 119-123
    CrossrefGoogle Scholar
  • 16 Petersenn S, Quabbe HJ, Schofl C et al. The rational use of pituitary stimulation tests. Dtsch Arztebl Int 2010; 107: 437-443
    Google Scholar
  • 17 Schneider HJ, Kosilek RP, Gunther M et al. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J Clin Endocrinol Metab 2011; 96 (07) 2074-80
    CrossrefGoogle Scholar
  • 18 Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011; 7: 279-289
    CrossrefGoogle Scholar
  • 19 van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97: 1589-1597
    CrossrefGoogle Scholar
  • 20 Whitelaw BC, Dworakowska D, Thomas NW et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 2012; 76: 877-886
    CrossrefGoogle Scholar